Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40036010.
- Also identified by DOI 10.1158/1078-0432.CCR-24-4368 and PMC identifier 12081179.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The shared HLA-bound neoepitopes in pancreatic ductal adenocarcinoma (PDAC) represent a novel class of noncanonical antigens with single amino acid substitutions resulting from translational errors. These peptides, shared across patients with PDAC, showed higher immunogenicity than wild-type counterparts, offering potential candidates for specific immunotherapy development in PDAC. See related article by Zhang et al., p. 1956.
Medical subject headings
- Pancreatic Neoplasms
- Immunotherapy
- Carcinoma, Pancreatic Ductal
- Epitopes
- Antigens, Neoplasm
- HLA Antigens